nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.04.2011 | Review

Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy

verfasst von: S. Balachandar, A. Katyal

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Cerebral malaria (CM) is a global life-threatening complication of Plasmodium infection and represents a major cause of morbidity and mortality among severe forms of malaria. Despite developing knowledge in understanding mechanisms of pathogenesis, the current anti-malarial agents are not sufficient due to drug resistance and various adverse effects. Therefore, there is an urgent need for the novel target and additional therapy. Recently, peroxisome proliferator-activated receptor (PPAR) a nuclear receptors (NR) and agonists of its isoforms (PPARγ, PPARα and PPARβ/δ) have been demonstrated to exhibit anti-inflammatory and immunomodulatory properties, which are driven to a new approach of research on inflammatory diseases. Although many studies on PPARs have confirmed their diverse biological role, there is a lack of knowledge of its therapeutic use in CM. The major objective of this review is to explore the possible experimental studies to link these two areas of research. We focus on the data describing the beneficial effects of this receptor in inflammation, which is observed as a basic pathology in CM. In conclusion, PPARs could be a novel target in treating inflammatory diseases, and continued work with the available and additional agonists screened from various sources may result in a potential new treatment for CM.

Moxon CA, Heyderman RS, Wassmer SC (2009) Dysregulation of coagulation in cerebral malaria. Mol Biochem Parasitol 166:99–108PubMed

Cox D, McConkey S (2010) The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci 67:557–568PubMed

Hora R, Bridges DJ, Craig A, Sharma A (2009) Erythrocytic casein kinase II regulates cytoadherence of Plasmodium falciparum-infected red blood cells. J Biol Chem 284:6260–6269PubMed

Jurzynski C, Gysin J, Pouvelle B (2007) CD44, a signal receptor for the inhibition of the cytoadhesion of CD36-binding Plasmodium falciparum-infected erythrocytes by CSA-binding infected erythrocytes. Microbes Infect 9:1463–1470PubMed

Pouvelle B, Matarazzo V, Jurzynski C, Nemeth J, Ramharter M, Rougon G, Gysin J (2007) Cell adhesion molecule, a new cytoadhesion receptor for Plasmodium falciparum-infected erythrocytes capable of aggregation. Infect Immun 75:3516–3522PubMed

Picot S, Bienvenu AL, Konate S, Sissoko S, Barry A, Diarra E, Bamba K, Djimdé A, Doumbo OK (2009) Safety of epoietin–quinine drug combination in children with cerebral malaria in Mali. Malar J 169:8–24

Santos-Magalhães NS, Mosqueira VC (2010) Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 18:560–575

Odeh M (2001) The role of tumour necrosis factor-alpha in the pathogenesis of complicated falciparum malaria. Cytokine 14:8–11

Specht S, Sarite SR, Hauber I, Hauber J, Görbig UF, Meier C, Bevec D, Hoerauf A, Kaiser A (2008) The guanylhydrazone CNI-1493: an inhibitor with dual activity against malaria-inhibition of host cell pro-inflammatory cytokine release and parasitic deoxyhypusine synthase. Parasitol Res 102:1177–1184PubMed

10.

Singh AP, Surolia N, Surolia A (2009) Triclosan inhibit the growth of the late liver-stage of Plasmodium. IUBMB Life 61:923–928PubMed

11.

Konieczna A, Lichnovka R, Erdosova B, Ehrmann J (2009) The role of PPARs in MDR—a lesson from embryonic development. Neoplasma 56:279–283PubMed

12.

Bishop-Bailey D, Bystrom J (2009) Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacol Ther 124:141–150PubMed

13.

Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernández-López D, Pradillo JM, Caso JR, Vivancos J, Nombela F, Serena J, Lizasoain I, Moro MA (2009) Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPAR gamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 29:3875–3884PubMed

14.

Ramanan S, Zhao W, Riddle DR, Robbins ME (2010) Role of PPARs in radiation-induced brain injury. PPAR Res 234:975

15.

Lin J, Chen A (2008) Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 88:529–540PubMed

16.

Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M (2010) Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 59:521–530PubMed

17.

Gimenez F, Barraud de Lagerie S, Fernandez C, Pino P, Mazier D (2003) Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life Sci 60:1623–1635PubMed

18.

Reimer T, Shaw MH, Franchi L, Coban C, Ishii KJ, Akira S, Horii T, Rodriguez A, Núñez G (2010) Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol 40:64–69

19.

Butthep P, Wanram S, Pattanapanyasat K, Vattanaviboon P, Fucharoen S, Wilairat P (2006) Cytoadherence between endothelial cells and P. falciparum infected and noninfected normal and thalassemic red blood cells. Cytom B Clin Cytom 70:432–442

20.

Howard RJ, Handunnetti SM, Hasler T, Gilladoga A, de Aguiar JC, Pasloske BL, Morehead K, Albrecht GR, van Schravendijk MR (1990) Surface molecules on Plasmodium falciparum-infected erythrocytes involved in adherence. Am J Trop Med Hyg 43:15–29PubMed

21.

Weinberg JB, Lopansri BK, Mwaikambo E, Granger DL (2008) Arginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria. Curr Opin Infect Dis 21:468–475PubMed

22.

Ohnishi K (2009) Cerebral malaria. Brain Nerve 61:122–128PubMed

23.

Armah H, Dodoo AK, Wiredu EK, Stiles JK, Adjei AA, Gyasi RK, Tettey Y (2005) High-level cerebellar expression of cytokines and adhesion molecules in fatal, paediatric, cerebral malaria. Ann Trop Med Parasitol 99:629–647PubMed

24.

Prato M, Gallo V, Giribaldi G, Arese P (2008) Phagocytosis of haemozoin (malarial pigment) enhances metalloproteinase-9 activity in human adherent monocytes: role of IL-1beta and 15-HETE. Malar J 157:8–17

25.

Belnoue E, Potter SM, Rosa DS, Mauduit M, Grüner AC, Kayibanda M, Mitchell AJ, Hunt NH, Rénia L (2008) Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria. Parasite Immunol 30:544–553PubMed

26.

Van den Steen PE, Deroost K, Van Aelst I, Geurts N, Martens E, Struyf S, Nie CQ, Hansen DS, Matthys P, Van Damme J, Opdenakker G (2008) CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol 38:1082–1095PubMed

27.

Brown H, Hien TT, Day N, Mai NT, Chuong LV, Chau TT, Loc PP, Phu NH, Bethell D, Farrar J, Gatter K, White N, Turner G (1999) Evidence of blood–brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 25:331–340PubMed

28.

Combes V, Coltel N, Faille D, Wassmer SC, Grau GE (2006) Cerebral malaria: role of microparticles and platelets in alterations of the blood–brain barrier. Int J Parasitol 36:541–546PubMed

29.

Newton CRJC, Krishna S (1998) Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 79:1–53PubMed

30.

Clark IA, Rockett KA, Cowden WB (1992) Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet 340:894–896PubMed

31.

Newton CR, Hien TT, White N (2000) Cerebral malaria. J Neurol Neurosurg Psychiatry 69:433–441PubMed

32.

Omari AA, Garner P (2007) Malaria: severe, life-threatening. Clin Evid (Online) July 2007, p 913

33.

Helmers AJ, Gowda DC, Kain KC, Liles WC (2009) Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages. Am J Trop Med Hyg 81:631–637PubMed

34.

Piguet PF, Kan CD, Vesin C (2002) Role of the tumor necrosis factor receptor 2 (TNFR2) in cerebral malaria in mice. Lab Invest 82:1155–1166PubMed

35.

Awasthi G, Singh S, Dash AP, Das A (2008) Genetic characterization and evolutionary inference of TNF-alpha through computational analysis. Braz J Infect Dis 12:374–379PubMed

36.

Randall LM, Engwerda CR (2010) TNF family members and malaria: old observations, new insights and future directions. Exp Parasitol 126:326–331PubMed

37.

Togbe D, de Sousa PL, Fauconnier M, Boissay V, Fick L, Scheu S, Pfeffer K, Menard R, Grau GE, Doan BT, Beloeil JC, Renia L, Hansen AM, Ball HJ, Hunt NH, Ryffel B, Quesniaux VF (2008) Both functional LTbeta receptor and TNF receptor 2 are required for the development of experimental cerebral malaria. PLoS ONE 9:e2608

38.

Amante FH, Haque A, Stanley AC, Rivera Fde L, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb BS, de Koning-Ward TF, Lundie RJ, Good MF, Pinzon-Charry A, Pearson MS, Duke MG, McManus DP, Loukas A, Hill GR, Engwerda CR (2010) Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J Immunol 185:3632–3642PubMed

39.

Jambou R, Combes V, Jambou MJ, Weksler BB, Couraud PO, Grau GE (2010) Plasmodium falciparum adhesion on human brain microvascular endothelial cells involves transmigration-like cup formation and induces opening of intercellular junctions. PLoS Pathog 29:e1001021

40.

Lundie RJ, de Koning-Ward TF, Davey GM, Nie CQ, Hansen DS, Lau LS, Mintern JD, Belz GT, Schofield L, Carbone FR, Villadangos JA, Crabb BS, Heath WR (2008) Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha + dendritic cells. Proc Natl Acad Sci USA 105:14509–14514PubMed

41.

Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, Buley ID, Gatter KC, Newbold CI, Pukritayakamee S, Nagachinta B et al (1994) An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 145:1057–1069PubMed

42.

Dietrich JB (2002) The adhesion molecule ICAM-1 and its regulation in relation with the blood–brain barrier. J Neuroimmunol 128:58–68PubMed

43.

Favre N, Da Laperousaz C, Ryffel B, Weiss NA, Imhof BA, Rudin W, Lucas R, Piguet PF (1999) Role of ICAM-1 (CD54) in the development of murine cerebral malaria. Microbes Infect 1:961–968PubMed

44.

Ockenhouse CF, Betageri R, Springer TA, Staunton DE (1992) Plasmodium falciparum-infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, Mac-1, and human rhinovirus. Cell 68:63–69PubMed

45.

Rénia L, Potter SM, Mauduit M, Rosa DS, Kayibanda M, Deschemin JC, Snounou G, Grüner AC (2006) Pathogenic T cells in cerebral malaria. Int J Parasitol 36:547–554PubMed

46.

Wassmer SC, Cianciolo GJ, Combes V, Grau GE (2005) Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med 2:e245PubMed

47.

Monso-Hinard C, Lou JN, Behr C, Juillard P, Grau GE (1997) Expression of major histocompatibility complex antigens on mouse brain microvascular endothelial cells in relation to susceptibility to cerebral malaria. Immunology 92:53–59PubMed

48.

Chen L, Zhang Z, Sendo F (2000) Neutrophils play a critical role in the pathogenesis of experimental cerebral malaria. Clin Exp Immunol 120:125–133PubMed

49.

Chen L, Sendo F (2001) Cytokine and chemokine mRNA expression in neutrophils from CBA/NSlc mice infected with Plasmodium berghei ANKA that induces experimental cerebral malaria. Parasitol Int 50:139–143PubMed

50.

Korthuis RJ, Anderson DC, Granger DN (1994) Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J Crit Care 9:47–71PubMed

51.

Pais TF, Chatterjee S (2005) Brain macrophage activation in murine cerebral malaria precedes accumulation of leukocytes and CD8+ T cell proliferation. J Neuroimmunol 163:73–83PubMed

52.

Szklarczyk A, Stins M, Milward EA, Ryu H, Fitzsimmons C, Sullivan D, Conant K (2007) Glial activation and matrix metalloproteinase release in cerebral malaria. J Neurovirol 3:2–10

53.

Kurtzhals JA, Reimert CM, Tette E, Dunyo SK, Koram KA, Akanmori BD, Nkrumah FK, Hviid L (1998) Increased eosinophil activity in acute Plasmodium falciparum infection—association with cerebral malaria. Clin Exp Immunol 112:303–307PubMed

54.

Waters LS, Taverne J, Tai PC, Spry CJ, Targett GA, Playfair JH (1987) Killing of Plasmodium falciparum by eosinophil secretory products. Infect Immun 55:877–881PubMed

55.

Camacho LH, Wilairatana P, Weiss G, Mercader MA, Brittenham GM, Looareesuwan S, Gordeuk VR (1999) The eosinophilic response and haematological recovery after treatment for Plasmodium falciparum malaria. Trop Med Int Health 4:471–475PubMed

56.

Good MF, Currier J (1992) The importance of T cell homing and the spleen in reaching a balance between malaria immunity and immunopathology: the moulding of immunity by early exposure to cross-reactive organisms. Immunol Cell Biol 70:405–410PubMed

57.

Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM, Miu J, Ball HJ (2006) Immunopathogenesis of cerebral malaria. Int J Parasitol 36:569–582PubMed

58.

Amante FH, Stanley AC, Randall LM, Zhou Y, Haque A, McSweeney K, Waters AP, Janse CJ, Good MF, Hill GR, Engwerda CR (2007) A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol 171:548–559PubMed

59.

Suidan GL, Mcdole JR, Chen Y, Pirko I, Johnson AJ (2008) Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS ONE 22:e3037

60.

Medana IM, Hunt NH, Chan-Ling T (1997) Early activation of microglia in the pathogenesis of fatal murine cerebral malaria. Glia 19:91–103PubMed

61.

Medana IM, Hunt NH, Chaudhri G (1997) Tumor necrosis factor-alpha expression in the brain during fatal murine cerebral malaria: evidence for production by microglia and astrocytes. Am J Pathol 150:1473–1486PubMed

62.

Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, Crabb BS, Heath WR, Engwerda CR, Hickey MJ, Schofield L, Hansen DS (2009) IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog 5(4):e1000369PubMed

63.

Rudin W, Eugster HP, Bordmann G, Bonato J, Müller M, Yamage M, Ryffel B (1997) Resistance to cerebral malaria in tumor necrosis factor-alpha/beta-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am J Pathol 150(1):257–266PubMed

64.

Bachmann MF, Schwarz K, Wolint P, Meijerink E, Martin S, Manolova V, Oxenius A (2004) Distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8 + T cells. J Immunol 173:2217–2221PubMed

65.

Potter S, Chan-Ling T, Ball HJ, Mansour H, Mitchell A, Maluish L, Hunt NH (2006) Perforin mediated apoptosis of cerebral microvascular endothelial cells during experimental cerebral malaria. Int J Parasitol 36:485–496PubMed

66.

Wassmer SC, Combes V, Candal FJ, Juhan-Vague I, Grau GE (2006) Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect Immun 74:645–653PubMed

67.

Couper KN, Barnes T, Hafalla JC, Combes V, Ryffel B, Secher T, Grau GE, Riley EM, de Souza JB (2010) Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. PLoS Pathog 29:e1000744

68.

Pino P, Vouldoukis I, Dugas N, Hassani-Loppion G, Dugas B, Mazier D (2003) Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann NY Acad Sci 1010:582–586PubMed

69.

Paterniti I, Esposito E, Mazzon E, Galuppo M, Di Paola R, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S (2010) Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther 333:465–477PubMed

70.

Lopansri BK, Anstey NM, Weinberg JB, Stoddard GJ, Hobbs MR, Levesque MC, Mwaikambo ED, Granger DL (2003) Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet 361:676–678PubMed

71.

Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS (1993) A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364:626–632PubMed

72.

Machado FS, Desruisseaux MS, Nagajyothi, Kennan RP, Hetherington HP, Wittner M, Weiss LM, Lee SC, Scherer PE, Tsuji M, Tanowitz HB (2006) Endothelin in a murine model of cerebral malaria. Exp Biol Med Maywood 231:1176–1181PubMed

73.

Enwonwu CO, Afolabi BM, Salako LO, Idigbe EO, Bashirelah N (2000) Increased plasma levels of histidine and histamine in falciparum malaria: relevance to severity of infection. J Neural Transm 107:1273–1287PubMed

74.

Noedl H, Youry Se, Schaecher K, Smith BL, Socheat D, Fukuda MM (2008) Evidence of artemisinin-resistant malaria in Western Cambodia . N Engl J Med 359;24. www.nejm.org. http://content.nejm.org/cgi/reprint/359/24/2619.pdf. Accessed 24 November 2010

75.

Jensen M, Mehlhorn H (2009) Seventy-five years of Resochin® in the fight against malaria. Parasitol Res 105:609–627PubMed

76.

WHO (2009) World malaria report 2009. WHO, Geneva. http://www.who.int/malaria/world_malaria_report_2009/en/index.html. Accessed 24 November 2010

77.

Meremikwu MM, Marson AG (2002) Routine anticonvulsants for treating cerebral malaria. Cochrane Database Syst Rev 2:CD002152

78.

Panisko DM, Keystone JS (1990) Treatment of malaria—1990. Drugs 39:160–189PubMed

79.

WHO (2005) World malaria report, 2005. WHO, Geneva

80.

WHO (2010) Guidelines for the treatment of malaria—2nd edition. WHO, Geneva

81.

Committee to Advice on Tropical Medicine and Travel (1995) Canadian recommendations for the prevention and treatment of malaria among international travellers. CCDR 21S3:1–18

82.

Waknine-Grinberg JH, Hunt N, Bentura-Marciano A, McQuillan JA, Chan HW, Chan WC, Barenholz Y, Haynes RK, Golenser J (2010) Artemisone effective against murine cerebral malaria. Malar J 9:227PubMed

83.

Zamidei L, Durval A, Bettocchi D, Luzzio MG, Bartoloni A, Consales G (2010) Efficacy and safety of quinine-artesunate in an HIV-positive patient with severe falciparum malaria. Minerva Anestesiol 76:66–69PubMed

84.

Lackner P, Part A, Burger C, Dietmann A, Broessner G, Helbok R, Reindl M, Schmutzhard E, Beer R (2009) Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study. Malar J 27:8–36

85.

Muniz-Junqueira MI (2007) Immunomodulatory therapy associated to anti-parasite drugs as a way to prevent severe forms of malaria. Curr Clin Pharmacol 2:59–73PubMed

86.

Chowdhury K, Bagasra O (2007) An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens. Med Hypotheses 68:22–30PubMed

87.

Jirage D, Keenan SM, Waters NC (2010) Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect Disord Drug Targets 10(3):134–146

88.

Donaldson T, Kim K (2010) Targeting Plasmodium falciparum purine salvage enzymes: a look at structure-based drug development. Infect Disord Drug Targets 10(3):191–199

89.

Allan RJ, Beattie P, Bate C, Van Hensbroek MB, Morris-Jones S, Greenwood BM, Kwiatkowski D (1995) Strain variation in tumor necrosis factor induction by parasites from children with acute falciparum malaria. Infect Immun 63:1173–1175PubMed

90.

Sanchez CP, Dave A, Stein WD, Lanzer M (2010) Transporters as mediators of drug resistance in Plasmodium falciparum. Int J Parasitol. doi:10.1016/j.ijpara.2010.04.001 PubMed

91.

Bloland PB (2001) Drug resistance in malaria. World Health Organization, Geneva, 534 WHO/CDC/DRS/2001.4

92.

World Health Organization (2006) Guidelines for the treatment of malaria. WHO, Geneva

93.

Talisuna AO, Bloland P, D'Alessandro U (2004) History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17:235–254PubMed

94.

Jackson Y, Chappuis F, Loutan L, Taylor W (2006) Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure? Malar J 5:81. doi:10.1186/1475-2875-5-81 PubMed

95.

Laufer M, Thesing P, Eddington N, Masonga R, Dzinjalamala F, Takala S, Taylor T, Plowe C (2006) Return of chloroquine antimalarial efficacy in Malawi. N Eng J Med 355:1959–1966

96.

Osei-Akoto A, Orton L, Owusu-Ofori SP (2005) Atovaquone-proguanil for treating uncomplicated malaria. Cochrane Database Syst Rev 19:CD004529

97.

White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7:549–558PubMed

98.

Wiwanitkit V (2009) Headache and malaria: a brief review. Acta Neurol Taiwan 18:56–59PubMed

99.

Vedy J, Graveline J, Carrica J, Rivaud C, Chanut G (1979) Retinopathy due to 4- aminoquinolines in the prevention of malaria. Bull Soc Pathol Exot Filiales 72:353–357PubMed

100.

Bertagnolio S, Tacconelli E, Camilli G, Tumbarello M (2001) Case report: Retinopathy after malaria prophylaxis with chloroquine. Am J Trop Med Hyg 65:637–638PubMed

101.

Phillips-Howard PA, Wood D (1996) The safety of antimalarial drugs in pregnancy. Drug Saf 14:131–145PubMed

102.

Mérat S, Lambert E, Vincenti-Rouquette I, Gidenne S, Rousseau JM, Brinquin L (2003) Case report: combination artemether-lumefantrine and haemolytic anaemia following a malarial attack. Trans R Soc Trop Med Hyg 97:433–434PubMed

103.

Busari O, Busari O (2008) Ventricular fibrillation in a 5-year-old child on therapeutic dose of quinine dihydrochloride infusion for acute malaria. J Natl Med Assoc 100:1063–1065PubMed

104.

Singhi S, Singhi P, Singh M (1979) Extrapyramidal syndrome following chloroquine therapy. Indian J Pediatr 46:58–60PubMed

105.

Busari OA, Oligbu G (2008) Chorea in a 29-year-old Nigerian following antimalarial treatment with artesunate. Int J Infect Dis 12:221–223PubMed

106.

Gürkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M, Hempel JM, Löscher T (2008) Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 7:179PubMed

107.

Leroy F, Bridoux F, Abou-Ayache R, Belmouaz S, Desport E, Thierry A, Bauwens M, Touchard G (2008) Quinine-induced renal bilateral cortical necrosis. Néphrol Thér 4:181–186PubMed

108.

Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ, d'Alessandro U, Modiano D (2008) High risk of severe anaemia after chlorproguanil-dapsone + artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS ONE 3:e4031PubMed

109.

Gupta GB, Varma S (2001) Effect of intravenous quinine on capillary glucose levels in malaria. J Assoc Physicians India 49:426–429PubMed

110.

Dyan AD (1998) Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use? Med Trop Mars 58:32–37

111.

Nosten F, McGready R, d'Alessandro U, Bonell A, Verhoeff F, Menendez C, Mutabingwa T, Brabin B (2006) Antimalarial drugs in pregnancy: a review. Curr Drug Saf 1:1–15PubMed

112.

Smith HJ, Meremikwu M (2003) Iron chelating agents for treating malaria. Cochrane Database Syst Rev 2:CD001474PubMed

113.

Bukirwa H, Garner P, Critchley J (2004) Chlorproguanil-dapsone for treating uncomplicated malaria. Cochrane Database Syst Rev 18:CD004387

114.

Waknine-Grinberg JH, McQuillan JA, Hunt N, Ginsburg H, Golenser J (2010) Modulation of cerebral malaria by fasudil and other immune-modifying compounds. Exp Parasitol 125(2):141–146

115.

Wang YX (2010) PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 20:124–137PubMed

116.

Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551–558PubMed

117.

Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48–52PubMed

118.

Maeda T, Kishioka S (2009) PPAR and pain. Int Rev Neurobiol 85:165–177PubMed

119.

Kostadinova R, Wahli W, Michalik L (2005) PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 12:2995–3009PubMed

120.

Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435PubMed

121.

Gelinas DS, McLaurin J (2005) PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. Neurochem Res 2005:1369–1375

122.

Lee JH, Joe EH, Jou I (2005) PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. NeuroReport 16:829–833PubMed

123.

Collino M, Patel NS, Thiemermann C (2005) PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2:179–197

124.

Feng D, Zhang Y, Chen G (2008) Cortical expression of peroxisome proliferator-activated receptor-alpha after human brain contusion. J Int Med Res 36:783–791PubMed

125.

Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C (2005) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts europrotective effects in traumatic brain injury. Neurosci Lett 388:7–12PubMed

126.

Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C (2007) Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 24:1119–1131PubMed

127.

Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264–6271PubMed

128.

Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 58(2):337–345

129.

Serghides L, Kain KC (2001) Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J Immunol 166:6742–6748PubMed

130.

Klotz L, Diehl L, Dani I, Neumann H, von Oppen N, Dolf A, Endl E, Klockgether T, Engelhardt B, Knolle P (2007) Brain endothelial PPARgamma controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro. J Neuroimmunol 190:34–43PubMed

131.

Sun H, Huang Y, Yu X, Li Y, Yang J, Li R, Deng Y, Zhao G (2008) Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats. Int J Dev Neurosci 26:505–515PubMed

132.

Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813–1826PubMed

133.

García-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC (2005) Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 57:885–894PubMed

134.

Wang CX, Ding X, Noor R, Pegg C, He C, Shuaib A (2009) Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 29:1683–1694PubMed

135.

Hyong A, Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813–1826

136.

Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J (2008) Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 1215:218–224PubMed

137.

Bernardo A, Minghetti L (2008) Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008:864–140

138.

Kumari R, Willing LB, Patel SD, Krady JK, Zavadoski WJ, Gibbs EM, Vannucci SJ, Simpson IA (2010) The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab 30:352–360PubMed

139.

Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L (2008) PPAR-gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches. PPAR Res 2008:295–784

140.

Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, Wilairatana P, Liles WC, Looareesuwan S, Kain KC (2009) Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 49:841–849PubMed

141.

Bernardo A, Bianchi D, Magnaghi V, Minghetti L (2009) Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol 68:97–808

142.

Sundararajan S, Jiang Q, Heneka M, Landreth G (2006) PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49:136–144PubMed

143.

Kwak H, Hwang I, Kim JH, Kim MY, Yang JS, Jeong S (2009) Modulation of transcription by the peroxisome proliferator-activated receptor β/γ–binding RNA aptamer in colon cancer cells. Mol Cancer Ther 8:2664–2673PubMed

144.

Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, Bishop-Bailey D (2009) Activation of PPAR /β/δ inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol 86:115–122PubMed

145.

al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940–1949PubMed

146.

Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63–69PubMed

147.

Ding G, Cheng L, Qin Q, Frontin S, Yang Q (2006) PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40:821–828PubMed

148.

Tan NS, Michalik L, Di-Poï N, Ng CY, Mermod N, Roberts AB, Desvergne B, Wahli W (2004) Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J 23:4211–4221PubMed

149.

Galuppo M, di Paola R, Mazzon E, Genovese T, Crisafulli C, Paterniti I, Cuzzocrea E, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S (2010) Role of PPAR-β/δ in the development of zymosan-induced multiple organ failure: an experiment mice study. J Inflamm Lond 18:7–12

150.

Kalinin S, Richardson JC, Feinstein DL (2009) A PPAR β/δ agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 6:431–437PubMed

151.

Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, Barone FC, Shearer BG, Barton ME, Kilgore KS (2008) Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPAR /β/δ ligand GW0742. Inflamm Res 57:314–321PubMed

152.

Defaux A, Zurich MG, Braissant O, Honegger P, Monnet-Tschudi F (2009) Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. J Neuroinflammation 7:6–15

153.

Rodríguez-Calvo R, Serrano L, Coll T, Moullan N, Sánchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vázquez-Carrera M (2008) Activation of peroxisome proliferator-activated receptor β/δ inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase ½. Diabetes 57:2149–2157PubMed

154.

Tripathi AK, Sha W, Shulaev V, Stins MF, Sullivan DJ Jr (2009) Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. Blood 114:4243–4252PubMed

155.

Lim HJ, Park JH, Lee S, Choi HE, Lee KS, Park HY (2009) PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur J Pharmacol 622:45–51PubMed

156.

Sheng L, Ye P, Liu YX, Han CG, Zhang ZY (2008) Peroxisome proliferator-activated receptor β/δ activation improves angiotensin II-induced cardiac hypertrophy in vitro. Clin Exp Hypertens 30:109–119PubMed

157.

Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ (2010) Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130(4):572–588

158.

Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303–308PubMed

159.

Schug TT, Li X (2009) PPAR delta-mediated macrophage activation: a matter of fat. Dis Model Mech 10:421–422

160.

Barish GD, Atkins AR, Downes M, Olson P, Chong LW, Nelson M, Zou Y, Hwang H, Kang H, Curtiss L, Evans RM, Lee CH (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 105:4271–4276PubMed

161.

Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 105:4277–4282PubMed

162.

Kim HJ, Kim MY, Jin H, Kim HJ, Kang SS, Kim HJ, Lee JH, Chang KC, Hwang JY, Yabe-Nishimura C, Kim JH, Seo HG (2009) Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/Smad3. Circ Res 105:16–24PubMed

163.

Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA (2006) Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 20:326–328PubMed

164.

Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA (2006) Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 34:242–246PubMed

165.

Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR (2004) PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23:8992–8996PubMed

166.

Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, Ricardo-Gonzalez RR, Goh YP, Eagle AR, Dunn SE, Awakuni JU, Nguyen KD, Steinman L, Michie SA, Chawla A (2009) PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med 15:1266–1272PubMed

167.

Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/γ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 105:418–428PubMed

168.

Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ (2010) Murine cerebral malaria is associated with a vasospasm-like microcirculatory dysfunction, and survival upon rescue treatment is markedly increased by nimodipine. Am J Pathol 176:1306–1315PubMed

169.

Hall MG, Quignodon L, Desvergne B (2008) Peroxisome proliferator-activated receptor /β/δ in the brain: facts and hypothesis. PPAR Res 2008(2008):780452PubMed

170.

Coll T, Rodrïguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer X, Vázquez-Carrera M (2009) Peroxisome proliferator-activated receptor (PPAR) /β/δ: a new potential therapeutic target for the treatment of metabolic syndrome. Curr Mol Pharmacol 2:46–55PubMed

171.

Erol A (2005) PPARalpha activators may be good candidates as anti-aging agents. Med Hypotheses 65:35–38PubMed

172.

Huang TH, Teoh AW, Lin BL, Lin DS, Roufogalis B (2009) The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 60:195–206PubMed

Titel: Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy
verfasst von: S. Balachandar
A. Katyal
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2011
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-010-1122-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Identification of the five human Plasmodium species including P. knowlesi by real-time polymerase chain reaction

The controlled in vitro susceptibility of gastrointestinal pathogens to the antibacterial effect of manuka honey

Calcineurin-dependent galactomannan release in Aspergillus fumigatus

Molecular detection and confirmation of Neisseria gonorrhoeae in urogenital and extragenital specimens using the Abbott CT/NG RealTime assay and an in-house assay targeting the porA pseudogene

In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints

Appropriateness of blood culture testing parameters in routine practice. Results from a cross-sectional study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin